Shares Investor Evening (London)

Presenting

Coro Energy (CORO)

Coro Energy is an oil and gas exploration company focused on delivering long-term production of natural gas. Coro Energy’s aim is to become a mid-tier, south east Asian focused exploration and production company. Last year, it completed the merger of SEHIL and Saffron Energy, integrating teams and assets under Coro Energy.

 

Destiny Pharma (DEST)

Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.

Destiny Pharma’s vision is of an expanding range of new antimicrobial drug products which operate within existing antibiotic markets but due to their unique features, open significant, new markets that are closed to traditional antibiotics due to the existence or threat of antibiotic resistance.

The proprietary, new antimicrobial drug platform at Destiny Pharma, the XF Drug Series, act via an ultra-rapid action which kill bacteria (including antibiotic resistant strains) leaving the bacteria unable to mount a resistance response.

 

Serica Energy

Serica is a British independent upstream oil and gas company with operations focused on the UK North Sea, where our assets span the full cycle of exploration, development and production.  Our main aim is to build a portfolio of assets which enables the Company to utilise its technical and commercial experience to add value to existing producing assets, as well as to explore and develop new reserves.

The Company has proved the success of this model through our producing asset, Erskine, in which we are a partner with Chevron and Chrysaor.  We have recently completed the purchase of interests in the Bruce, Keith and Rhum fields, where we have taken over as field operator.  Further investment will enhance recovery and extend field life of these fields, which are a mixture of late-life and mid-life, largely gas-producing assets.

VolitionRx

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

As cancer screening programs become more widespread, Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.